Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Rare Diseases 1Precancerous Conditions 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Muscle-invasive Bladder Cancer 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Hypertension, Portal 1Hepatitis C 1Fibrosis 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6Megestrol Acetate 4niraparib 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × tremelimumab × Clear all
NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡